Verteporfin photodynamic therapy for neovascular age-related ...

DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 683References1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam EyeStudy. Ophthalmology 1992;99:933–43.2. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al.The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology1995;102:205–10.3. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation inage-related macular degeneration with verteporfin: one-year results of 2 randomised clinicaltrials. TAP report 1. Arch Ophthalmol 1999;117:1239–45.4. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation inage-related macular degeneration with verteporfin: two-year results of 2 randomised clinicaltrials. TAP report 2. Arch Ophthalmol 2001;119:198–207.5. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfovealchoroidal neovascularization in pathologic myopia with verteporfin. 1-year results of arandomized clinical trial – VIP report no. 1. Ophthalmology 2001;108:841–52.6. National Institute for Clinical Excellence. The clinical effectiveness and cost effectiveness ofphotodynamic therapy for age-related macular degeneration; 2003. URL: www.nice.org.uk/guidance/TA68 (accessed 30 November 2010).7. Bren L. The importance of patient-reported outcomes … It’s all about patients. FDAConsumer Magazine 2006;40(6).8. UK Department of Health. Guidance on the routine collection of Patient Reported OutcomeMeasures (PROMs); 2009. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_092647 (accessed 30 November 2010).9. Brazier J, Ratcliffe J, Saloman JA, Tsuchiya A. Introduction to the measurement and valuationof health. In Measuring and valuing health benefits for economic evaluation. Oxford: OxfordUniversity Press; 2007. pp. 7–36.10. Bradley C. Importance of differentiating health status from quality of life. Lancet2001;357:7–8.11. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Developmentof the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol2001;119:1050–8.12. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality oflife. Health Pol 1990;16:119–208.13. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health fromthe SF-36. J Health Econ 2002;21:271–92.14. Gold M, Siegel J, Russel L, Weinstein M. Theoretical foundations of cost-effectivenessanalysis. In Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness inhealth and medicine. New York, NY: Oxford University Press; 1996. pp. 82–134.15. National Institute for Clinical Excellence. Updated guide to the methods of technologyappraisal; 2008. URL: www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp (accessed 4October 2009).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.